Our analysis of the epigenetic regulators that control p16 expression finds many commonalities between the hundreds of tumors making up the TCGA CESC and HNSC cohorts and cell culture models, strongly suggesting that testing of KDM6 inhibitors should be aggressively pursued as a novel therapy of HPV+ cancers. Here, CDKN2A is linked to cancer.